Australia - English - Department of Health (Therapeutic Goods Administration)

gedeon richter australia pty ltd - levonorgestrel, quantity: 1.5 mg - tablet, uncoated - excipient ingredients: potato starch; maize starch; purified talc; lactose monohydrate; colloidal anhydrous silica; magnesium stearate - emergency contraception within 72 hours of unprotected intercourse.

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratoire hra pharma - levonorgestrel - tablet - 1.5 milligram(s) - emergency contraceptives; levonorgestrel

Kenya - English - Pharmacy and Poisons Board

agile biotech rajkot-360 004 (gujarat india) - levonorgestrel tablets bp - tablet - 0.75mg - emergency contraceptives for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - quetiapine fumarate, quantity: 230.284 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; sodium starch glycollate type a; magnesium stearate; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; macrogol 400 - quetiapine rbx tablets are indicated for: bipolar disorder = maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes = treatment of depressive episodes associated with bipolar disorder (see dosage and administration) = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate schizophrenia = treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - quetiapine fumarate, quantity: 28.785 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; calcium hydrogen phosphate dihydrate; povidone; sodium starch glycollate type a; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - quetiapine rbx tablets are indicated for: bipolar disorder = maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes = treatment of depressive episodes associated with bipolar disorder (see dosage and administration) = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate schizophrenia = treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - quetiapine fumarate, quantity: 115.142 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; sodium starch glycollate type a; lactose monohydrate; calcium hydrogen phosphate dihydrate; povidone; titanium dioxide; hypromellose; purified talc; macrogol 400 - quetiapine rbx tablets are indicated for: bipolar disorder = maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes = treatment of depressive episodes associated with bipolar disorder (see dosage and administration) = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate schizophrenia = treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - quetiapine fumarate, quantity: 345.425 mg (equivalent: quetiapine, qty 300 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; calcium hydrogen phosphate dihydrate; sodium starch glycollate type a; microcrystalline cellulose; povidone; magnesium stearate; titanium dioxide; hypromellose; purified talc; macrogol 400 - quetiapine rbx tablets are indicated for: bipolar disorder = maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes = treatment of depressive episodes associated with bipolar disorder (see dosage and administration) = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate schizophrenia = treatment of schizophrenia

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 2 mg - tablet, uncoated - excipient ingredients: sodium benzoate; docusate sodium; maize starch; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate; povidone; microcrystalline cellulose; lactose - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 1 mg - tablet, uncoated - excipient ingredients: indigo carmine; docusate sodium; sodium benzoate; lactose; sodium starch glycollate; povidone; magnesium stearate; maize starch; colloidal anhydrous silica; microcrystalline cellulose - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - alprazolam, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; maize starch; lactose; povidone; sodium benzoate; magnesium stearate; microcrystalline cellulose; docusate sodium; sodium starch glycollate; colour - anxiety: the short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression, and panic disorder: the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks.